These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38526177)

  • 41. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
    Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
    PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stage-specificity of STING activation in intrahepatic cholangiocarcinoma determines the efficacy of its agonism.
    Luo S; Li S; Liu C; Yu D; Sun L; Zhang S; Zhao N; Zhang M; Nie J; Zhao Y; Li C; Zhang Y; Zhang Q; Meng H; Li X; Shi J; Zheng T
    Cancer Lett; 2024 Jul; 594():216992. PubMed ID: 38797231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma.
    Yang G; Zong H
    Mol Med Rep; 2016 Jun; 13(6):4786-90. PubMed ID: 27082702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.
    Garg M; Kanojia D; Okamoto R; Jain S; Madan V; Chien W; Sampath A; Ding LW; Xuan M; Said JW; Doan NB; Liu LZ; Yang H; Gery S; Braunstein GD; Koeffler HP
    J Clin Endocrinol Metab; 2014 Jan; 99(1):E62-72. PubMed ID: 24170107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M
    J Hepatol; 2024 Aug; 81(2):265-277. PubMed ID: 38508240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.
    Angenard G; Merdrignac A; Louis C; Edeline J; Coulouarn C
    Dig Liver Dis; 2019 Sep; 51(9):1337-1343. PubMed ID: 31040073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection.
    Huang J; Wang X; Zhu Y; Wang Z; Li J; Xu D; Wang S; Li TE; Lu L
    J Surg Oncol; 2019 Jan; 119(1):40-46. PubMed ID: 30480811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Yang LX; Gao Q; Shi JY; Wang ZC; Zhang Y; Gao PT; Wang XY; Shi YH; Ke AW; Shi GM; Cai JB; Liu WR; Duan M; Zhao YJ; Ji Y; Gao DM; Zhu K; Zhou J; Qiu SJ; Cao Y; Tang QQ; Fan J
    Hepatology; 2015 Dec; 62(6):1804-16. PubMed ID: 26340507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Loss of α-1,2-mannosidase MAN1C1 promotes tumorigenesis of intrahepatic cholangiocarcinoma through enhancing CD133-FIP200 interaction.
    Wei Y; Chen Q; Chen J; Zhou C; Geng S; Shi D; Huang S; Liang Z; Chen X; Ren N; Jiang J
    Cell Rep; 2023 Dec; 42(12):113588. PubMed ID: 38117655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells.
    Gui A; Kobayashi A; Motoyama H; Kitazawa M; Takeoka M; Miyagawa S
    BMC Cancer; 2012 May; 12():179. PubMed ID: 22591401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
    Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
    Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
    Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    Song X; Xu H; Wang P; Wang J; Affo S; Wang H; Xu M; Liang B; Che L; Qiu W; Schwabe RF; Chang TT; Vogl M; Pes GM; Ribback S; Evert M; Chen X; Calvisi DF
    J Hepatol; 2021 Oct; 75(4):888-899. PubMed ID: 34052254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative Proteomics Reveals Down-Regulated Glycolysis/Gluconeogenesis in the Large-Duct Type Intrahepatic Cholangiocarcinoma.
    Guo Y; Li Q; Ren W; Wu H; Wang C; Li X; Xue B; Qiu Y; Zhang J; Chen J; Fang L
    J Proteome Res; 2022 Oct; 21(10):2504-2514. PubMed ID: 36066509
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 59. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling.
    Tang Z; Yang Y; Chen W; Liang T
    Hepatol Commun; 2023 Aug; 7(8):. PubMed ID: 37486965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.